Yoshizaki T, Tabuchi N, van Oeveren W, Shibamiya A, Koyama T, Sunamori M
Department of Cardio-Thoracic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Int J Artif Organs. 2005 Aug;28(8):834-40. doi: 10.1177/039139880502800809.
Poly(2-methoxyethylacrylate) (PMEA) is a new coating material that appears to reduce protein and platelet adsorption. However, the exact performance of PMEA coated circuit remains to be revealed in well-controlled experiments. Therefore, we compared its hemocompatibility with covalent-bound heparin-, and non-coated circuits during 6 hours of in vitro circulation, using donor blood from six volunteers. In our model, simple tubing circuits containing one-way ball valve were placed on the rotary table, which moved alternatively to generate pulsatile recirculation of heparinized human blood inside the tubing. Using this model, we expected fine assessment of the material surface, because we could reduce blood damage by avoiding air and a blood pump. Moreover, the small capacity of circuit allowed us to compare three kinds of circuits using a single unit of donor blood, eliminating effects by possible variations between blood donors. The anti-thrombin capacity of the PMEA-coated circuits was maintained even after six hours blood circulation, whereas surface thrombin generation increased markedly after use in non-coated circuits (P<0.05). Deposition of fibrin onto PMEA circuits was reduced more than 30% compared with heparin and non-coated circuits (P<0.05). However, the increase of plasma Factor XIIa was similar in all circuits. Increase of CD11b expression on circulating leukocytes and of plasma C3a was ameliorated in the heparin- and PMEA-coated circuits (P<0.05). PMEA-coated circuits appear to maintain their anti-thrombogenicity during use, otherwise PMEA-coated and heparin-coated circuits showed a similar character in hemocompatibility. This long-standing anti-thrombogenicity might be attributable to less adsorption of activated blood components onto the surface.
聚（甲基丙烯酸2 - 甲氧基乙酯）（PMEA）是一种新型涂层材料，似乎能减少蛋白质和血小板吸附。然而，PMEA涂层回路的确切性能仍有待在严格控制的实验中揭示。因此，我们使用六名志愿者的献血，在体外循环6小时期间，比较了其与共价结合肝素涂层回路和未涂层回路的血液相容性。在我们的模型中，将包含单向球阀的简单管道回路放置在旋转台上，旋转台交替移动以在管道内产生肝素化人体血液的搏动再循环。使用该模型，我们期望能对材料表面进行精细评估，因为我们可以通过避免空气和血泵来减少血液损伤。此外，回路的小容量使我们能够使用单个献血单位比较三种回路，消除了献血者之间可能的差异所产生的影响。即使在血液循环6小时后，PMEA涂层回路的抗凝血酶能力仍得以维持，而未涂层回路使用后表面凝血酶生成显著增加（P<0.05）。与肝素涂层回路和未涂层回路相比，PMEA回路中纤维蛋白的沉积减少了30%以上（P<0.05）。然而，所有回路中血浆因子XIIa的增加情况相似。肝素涂层回路和PMEA涂层回路中循环白细胞上CD11b表达的增加以及血浆C3a的增加有所改善（P<0.05）。PMEA涂层回路在使用过程中似乎能保持其抗血栓形成性，否则PMEA涂层回路和肝素涂层回路在血液相容性方面表现出相似的特征。这种长期的抗血栓形成性可能归因于活化血液成分在表面的吸附较少。
